SCHEMBL8245481

SCHEMBL8245481

CCC[C@H](C)C(=O)OCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CYP3A4 P08684 2/20 0.41
POLB P06746 2/20 0.41
CYP2C19 P33261 1/20 0.41
GAA P10253 2/20 0.40
ALOX15 P16050 1/20 0.40
MGAM O43451 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
SOAT1 P35610 1/20 0.40
CHRM1 P11229 1/20 0.39
AKR1A1 P14550 1/20 0.39
CHRM3 P20309 1/20 0.39
HTR2A P28223 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113543 1.00 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL13483255 1.00 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL18669389 0.98 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL28227396 0.98 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
Phosphine SCHEMBL27449508 0.98 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL28254365 0.95 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL30074139 0.93 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
Ethyl Acetate SCHEMBL28096321 0.91 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL29411185 0.91 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E
SCHEMBL14616914 0.90 ALDH1A1 (0.48) ALDH1A1MEN1KMT2ALMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2612851-B1 Process for the preparation of the L-arginine salt of perindopril SERVIER LAB (FR) 2016-07-06 EP disclosed
EP-1989182-B1 CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT SERVIER LAB (FR) 2016-04-13 EP disclosed
US-8754135-B2 Functionalized non-phenolic amino acids and absorbable polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2014-06-17 US disclosed
EP-2612850-B1 Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it SERVIER LAB (FR) 2013-09-18 EP disclosed
US-8519156-B2 Functionalized non-phenolic amino acids and absorbable polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-08-27 US disclosed
WO-2013102741-A1 DELTA-CRYSTALLINE FORM OF PERINDOPRIL ARGININE SALT, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2013-07-11 WO disclosed
WO-2013102740-A1 METHOD FOR THE PREPARATION OF PERINDOPRIL ARGININE SALT LES LABORATOIRES SERVIER (FR) 2013-07-11 WO disclosed
EP-2612850-A1 Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it Les Laboratoires Servier (FR) 2013-07-10 EP disclosed
EP-2612851-A1 Process for the preparation of the L-arginine salt of perindopril Les Laboratoires Servier (FR) 2013-07-10 EP disclosed
US-20130116446-A1 FUNCTIONALIZED NON-PHENOLIC AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2013-05-09 US disclosed
US-7323575-B2 Process for the synthesis of (2S)-indoline-2-carboxylic acid LES LABORATORIES SERVIER (FR) 2008-01-29 US disclosed
US-7323575-B2 Process for the synthesis of (2S)-indoline-2-carboxylic acid LES LABORATORIES SERVIER (FR) 2008-01-29 US disclosed
US-7279583-B2 Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof LES LABORATOIRES SERVIER (FR) 2007-10-09 US disclosed
US-20070197821-A1 Process for the preparation of high purity perindopril LES LABORATOIRES SERVIER (FR) 2007-08-23 US disclosed
EP-1268424-B1 METHOD FOR SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS SERVIER LAB (FR) 2007-08-08 EP disclosed
EP-1333026-B1 Process for the preparation of high purity perindopril and intermediates useful in the synthesis SERVIER LAB (FR) 2007-06-27 EP disclosed
US-20070112204-A1 Process for the synthesis of (2S)-indoline-2-carboxylic acid LES LABORATOIRES SERVIER (FR) 2007-05-17 US disclosed
US-20070112204-A1 Process for the synthesis of (2S)-indoline-2-carboxylic acid LES LABORATOIRES SERVIER (FR) 2007-05-17 US disclosed
WO-2007017894-A2 PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE ARCH PHARMALABS LIMITED (IN) 2007-02-15 WO disclosed
EP-1422236-B1 Method for synthesis of perindopril and its pharmaceutically acceptable salts SERVIER LAB (FR) 2007-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197821-A1 Process for the preparation of high purity perindopril ACE, AGTR1, ACE2 SMN1; SMN2 2111/4885ALDH1A1 142/4885MEN1 4424/4885
US-20130116446-A1 FUNCTIONALIZED NON-PHENOLIC AMINO ACIDS AND ABSORBABLE POLYMERS THEREFROM SLC1A5, SLC7A1, BCAT2 SMN1; SMN2 4296/4885ALDH1A1 1525/4885MEN1 3775/4885
US-20070112204-A1 Process for the synthesis of (2S)-indoline-2-carboxylic acid IMPDH2, PDK4, QDPR SMN1; SMN2 1824/4885ALDH1A1 74/4885MEN1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.